Karyopharm Therapeutics Inc
Statements
Cash Flow
Karyopharm Therapeutics Inc (KPTI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -25 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20 | -20 | -25 | -22 | -22 | -5.5 | -35 | -38 | -39 | -48 | -67 | -48 | -37 | -39 | -45 | -40 | -44 | -31 | -53 | -56 | -24 | 25 | -59 | -35 | -28 | -27 | -19 | -26 | -30 | -19 | -44 | -38 | -19 | -26 | -39 | -19 | -5.9 | -12 | -23 | -25 | -65 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 2.1 | 2.2 | 2.2 | 2.3 | 2.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.4 | 0.4 | 0.2 | 0.1 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.1 | 2.5 | 2.4 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 5.6 | 5.1 | 5.9 | 5.1 | 4.9 | 4.5 | 4.2 | 4.4 | 4.8 | 3.9 | 3.9 | 4.1 | 3.7 | 3.5 | 5.2 | 6.4 | 6.5 | 6.3 | 7.4 | 8.1 | 7.4 | 6.9 | 7.3 | 15 | 6.8 | 6.2 | 5.4 | 6.1 | 5.1 | 5.2 | 5.0 | 5.4 | 4.2 | 3.9 | 3.6 | 3.8 | 2.8 | 3.9 | 3.0 | 1.9 | 12 | |
| 5.6 | 5.1 | 5.9 | 5.1 | 4.9 | 4.5 | 4.2 | 4.4 | 4.8 | 3.9 | 3.9 | 4.1 | 3.7 | 3.5 | 5.2 | 6.4 | 6.5 | 6.1 | 8.1 | 8.2 | 15 | 7.3 | 7.3 | 15 | 6.8 | 5.9 | 5.4 | 5.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.9 | 1.3 | -1.2 | 2.0 | 3.5 | 29 | -0.7 | -8.7 | 4.4 | 4.8 | -5.8 | -10 | -0.6 | 5.7 | 0.9 | 0.4 | -0.7 | 1.5 | -2.3 | -10 | 14 | -22 | -27 | 0.3 | 1.1 | 5.9 | 10 | 8.4 | 1.9 | 17 | -13 | -9.5 | 7.5 | 10 | -1.5 | 10 | 14 | 5.5 | 3.9 | 1.3 | 25 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.4 | 0.5 | 1.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -5.0 | 6.6 | 0.5 | -1.1 | 21 | -2.9 | 2.5 | -28 | 21 | -103 | 32 | 40 | 40 | -34 | -46 | -60 | 21 | 31 | 43 | 46 | 21 | 31 | -14 | -37 | 12 | -65 | -32 | 21 | -7.7 | 27 | 22 | 51 | 7.5 | 15 | 15 | 18 | 4.8 | 5.0 | 3.2 | -10 | 3.0 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.2 | 0.1 | 0.2 | 0.2 | 0.4 | 0.4 | 1.4 | 0.8 | 0.9 | 0.2 | 0.4 | 0.6 | 3.4 | 2.7 | 2.3 | 1.2 | 4.0 | 0.8 | 2.1 | 0.0 | 0.9 | 1.5 | 1.3 | 0.0 | 1.2 | – | – | – | – | – | – | 111 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 167 | 167 | 167 | 167 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 41 | – | – | 0.0 | 27 | – | – | – | |
| 31 | 19 | 0.1 | 53 | 0.2 | 23 | 0.4 | 147 | 0.8 | 168 | 0.2 | 0.4 | 89 | 35 | 165 | 2.0 | 1.2 | 4.0 | 11 | 62 | 0.0 | 0.9 | 31 | 1.3 | 5.8 | 156 | 0.0 | 0.9 | 39 | 0.3 | – | 41 | 0.0 | 0.7 | 0.0 | 0.4 | 0.0 | 30 | 50 | -0.9 | 79 | |
| 6.2 | 5.8 | -24 | 30 | -0.9 | 15 | -32 | 82 | -17 | 16 | -35 | -8.0 | 92 | -38 | 73 | -98 | -22 | 5.0 | 0.9 | 53 | -2.3 | 57 | -43 | -71 | -11 | 64 | -51 | -3.7 | -37 | 8.6 | -22 | 54 | -12 | -10 | -24 | 0.0 | -1.1 | 23 | 30 | -36 | 16 | |
| -20 | -20 | -25 | -22 | -22 | -5.6 | -35 | -38 | -39 | -49 | -67 | -48 | -37 | -40 | -45 | -40 | -44 | -31 | -53 | -56 | -24 | 25 | -59 | -35 | -28 | -27 | -19 | -26 | -30 | -19 | -44 | -38 | -19 | -26 | -39 | -19 | -5.9 | -12 | -23 | -25 | -65 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.